CTIS2022-502975-45-00RecruitingPhase 1
Randomized, Controlled, Open-label, Phase IIb/III Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Patients with Metastatic Leiomyosarcoma - PM1183-C-010-22
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Pharma Mar S.A.
- Enrollment
- 297
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 65+ (—)
- Sex
- All
Inclusion Criteria
- •Voluntary signed and dated written informed consent of the patient, obtained before any study-specific procedure., Age = 18 years., Histologically confirmed diagnosis of metastatic LMS, in patients not candidates for curative resection., Radiologically measurable disease according to the RECIST v.1.1., No previous systemic therapy for metastatic disease (i.e., first-line setting) and no previous anthracyclines. Note: prior chemotherapy (without anthracycline) in the context of adjuvant or neoadjuvant therapy is allowed., Eastern Cooperative Oncology Group (ECOG) performance status (PS) = 1., Adequate hematological, renal, metabolic and hepatic function: a) Hemoglobin = 9.0 g/dL [patients may have received prior red blood cell (RBC) transfusion]; absolute neutrophil count (ANC) = 2.0 x 109/L, and platelet count = 100 x 109/L. b) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 3.0 x upper limit of normal (ULN). c) Total bilirubin = ULN or direct bilirubin = ULN if total bilirubin is > ULN. d) Albumin = 3.0 g/dL. e) Calculated creatinine clearance (CrCL) = 30 mL/min (using Cockcroft and Gault’s formula). f) Left ventricular ejection fraction (LVEF) > 50% assessed by multiple-gated acquisition scan (MUGA) or echocardiography (ECHO)., Wash-out periods: a) At least three weeks since last prior systemic treatment. b) At least three weeks since last prior major surgery and one week since last prior minor surgery. c) At least two weeks since last prior radiotherapy., Evidence of non-childbearing status for women of childbearing potential (WOCBP). WOCBP must agree to use a highly effective contraceptive measure up to seven months after treatment discontinuation. Valid methods to determine the childbearing potential, adequate contraception and requirements for WOCBP partners are described in APPENDIX 2. Fertile male patients with WOCBP partners should use condoms during treatment and for four months following the last investigational medicinal product (IMP) dose.
Exclusion Criteria
- •Prior treatment with anthracyclines, lurbinectedin or trabectedin., Limitation of the patient’s ability to comply with the treatment or to follow-up the protocol., Patients in whom rapid tumor shrinkage is needed (e.g., when a tumor is close to a critical structure). * Women of childbearing potential (WOCBP) must agree to use a highly effective contraception method to avoid pregnancy during the course of the trial (and for at least seven months after the last infusion). Fertile male patients must agree to refrain from fathering a child or donating sperm during the trial and for four months after the last infusion. Valid methods to determine childbearing potential, adequate contraception and requirements of WOCBP partners are described in APPENDIX 2., Women who are pregnant or breast feeding and fertile patients (men and women) who are not using a highly effective method of contraception.* * Women of childbearing potential (WOCBP) must agree to use a highly effective contraception method to avoid pregnancy during the course of the trial (and for at least seven months after the last infusion). Fertile male patients must agree to refrain from fathering a child or donating sperm during the trial and for four months after the last infusion. Valid methods to determine childbearing potential, adequate contraception and requirements of WOCBP partners are described in APPENDIX 2., Known low grade leiomyosarcoma (i.e., grade I)., Known hypersensitivity to any of the components of the i.v. formulation of lurbinectedin or doxorubicin., Concomitant diseases/conditions: a) History of cardiac disease: myocardial infarction or angina; severe valvular disease or symptomatic arrhythmia despite ongoing treatment. b) Patients with any immunodeficiency, including those known to be infected by human immunodeficiency virus (HIV). c) Known chronic active hepatitis or cirrhosis. For Hepatitis B, this includes positive tests for both Hepatitis B surface antigen and quantitative Hepatitis B polymerase chain reaction (PCR). For Hepatitis C, this includes positive tests for both Hepatitis C antibody and quantitative Hepatitis C PCR. d) Active uncontrolled infection. e) Any other major illness (including severe cardiovascular disease) or risk factorsthat, in the Investigator’s judgment, will substantially increase the risk associated with the patient’s participation in this study., Use of strong inducers of CYP3A activity within two weeks prior to the first infusion of lurbinectedin., Prior irradiation if only one target lesion (i.e., measurable) is available, unless progression of the lesion has been confirmed., Known myopathy., History of another neoplastic disease except for curatively treated basal cell carcinoma, squamous cell carcinoma of the skin, properly treated carcinoma in situ of the uterine cervix or breast or superficial bladder tumors (Ta, Tis, or T1) that have been successfully and curatively treated with no evidence of recurrent or residual disease within three years prior to randomization. In case of prior malignancy, the Investigator should ensure, based on histology or clinical information, that the metastatic sites are sarcoma and not recurrence of the original malignancy.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Efficacy, safety and immunogenicity study of GSK Biologicals’ candidate malaria vaccine (SB257049) evaluating schedules with or without fractional doses, early Dose 4 and yearly doses, in children 5-17 months of ageHealthy volunteers (primary immunization against malaria disease caused by Plasmodium falciparum)MedDRA version: 20.0Level: PTClassification code 10025487Term: MalariaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-000290-20-Outside-EU/EEAGlaxoSmithKline Biologicals1,500
Active, not recruiting
Phase 1
Trial of Rosuvastatin for the Prevention of Kidney Toxicity caused by Tobramycin in Children with Cystic FibrosisEUCTR2014-002387-32-GBniversity of Liverpool50
Active, not recruiting
Phase 1
A phase II, open- label, controlled, randomized, multicenter study to evaluate the efficacy and safety of pertuzumab (Omnitarg™), a recombinant humanized antibody against HER2, in combination with carboplatin-based standard chemotherapy versus carboplatin-based standard chemotherapy alone in patients with platinum-sensitive recurrent ovarian cancerPlatinum sensitive recurrent ovarian cancerEUCTR2005-000557-30-GBF. Hoffmann-La Roche Ltd148
Active, not recruiting
Not Applicable
A phase II, open- label, controlled, randomized, multicenter study to evaluate the efficacy and safety of pertuzumab (Omnitarg™), a recombinant humanized antibody against HER2, in combination with carboplatin-based standard chemotherapy versus carboplatin-based standard chemotherapy alone in patients with platinum-sensitive recurrent ovarian cancerPlatinum sensitive recurrent ovarian cancerEUCTR2005-000557-30-BEF. Hoffmann-La Roche Ltd148
Active, not recruiting
Not Applicable
A phase II, open- label, controlled, randomized, multicenter study to evaluate the efficacy and safety of pertuzumab (Omnitarg™), a recombinant humanized antibody against HER2, in combination with carboplatin-based standard chemotherapy versus carboplatin-based standard chemotherapy alone in patients with platinum-sensitive recurrent ovarian cancerEUCTR2005-000557-30-HUF. Hoffmann-La Roche Ltd148